Squamous cell carcinoma is one of the most common and aggressive types of cancer in the head and neck region. It is the fifth ...

Prognosis is extremely poor for patients with head and neck squamous cell carcinoma (HNSCC), which accounts for around 90% of all head and neck cancer. Especially in the more aggressive subtype of ...

Esophageal cancer occurring in patients with head and neck squamous cell carcinoma (HNSCC) represents a critical clinical challenge, as these secondary tumours notably worsen patient prognosis. Owing ...

Please provide your email address to receive an email when new articles are posted on . Patients who received nivolumab had longer DFS than those who received standard care. OS will be evaluated after ...

Keytruda and Efti combination therapy achieved a median overall survival of 17.6 months in head and neck squamous cell carcinoma with PD-L1 CPS less than one. The combination therapy demonstrated a ...

Compared with standard concurrent chemoradiation, neoadjuvant chemotherapy followed by transoral robotic surgery (NECTORS) and neck dissection led to superior distant metastasis-free and overall ...

BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the ...

(ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR ...